Business
Orthocell (ASX:OCC) share price jumps 17% on positive clinical trials
The Orthocell Ltd (ASX: OCC) share price is 17% higher this morning, after the company released positive results in its CelGro nerve repair study. At the time of writing, Orthocell shares are trading at 44 cents per share.
About Orthocell
Orthocell is a regenerative medicine company dedicated to the development of novel collagen medical devices and cellular therapies for the repair and regeneration of human tendons, bone, nerve and cartilage defects.
The company’s regenerative medicine products include CelGro, a naturally derived collagen medical device for tissue repair. CelGro is designed for use in multiple indications to augment the surgical repair of tendons, bone, peripheral nerves and articular cartilage.
The product…
-
General23 hours agoFederal government funding extends cohealth GP services until July 2026
-
General7 hours agoMildura man given 28 years to pay $73,000 in unpaid fines and tolls
-
Noosa News21 hours agoSunshine Coast Airport receives green light for major upgrade opening doors to growth jobs and tourism across the region
-
General10 hours agoAustralia’s race to rewire the country amid a global transmission boom is not unique